ArticleThe Lancet. Oncology2016
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Dong-Wan Kim et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
234 papers cite itlatest 60 shown
this paperpooled ittrialcites it